Uncorrected Proof scheduled for 18 (1)

Molecular Characterization of Drug Resistance in Hepatitis B Viruses Isolated from Patients with Chronical Infection in Turkey

Authors Information
Article Notes and Dates
To Cite : Asan A, Sayan M, Akhan S, Tekin Koruk S, Aygen B, et al. Molecular Characterization of Drug Resistance in Hepatitis B Viruses Isolated from Patients with Chronical Infection in Turkey, Hepat Mon. Online ahead of Print ;In Press(In Press):e12472. doi: 10.5812/hepatmon.12472.
Copyright: Copyright © 0, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Miller RH, Kaneko S, Chung CT, Girones R, Purcell RH. Compact organization of the hepatitis B virus genome. Hepatology. 1989;9(2):322-7. [PubMed: 2643549].
  • 2. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology. 2002;293(2):305-13. doi: 10.1006/viro.2001.1246. [PubMed: 11886250].
  • 3. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006;44(6):1656-65. doi: 10.1002/hep.21422. [PubMed: 17133475].
  • 4. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol. 2008;48 Suppl 1:S2-19. doi: 10.1016/j.jhep.2008.01.011. [PubMed: 18304680].
  • 5. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int. 2008;2(2):147-51. doi: 10.1007/s12072-008-9048-3. [PubMed: 19669299].
  • 6. Mistik R. Viral hepatit. In: Tabak, F , Balik, İ , Tekeli, E , editors. 1. Istanbul: VHSD; 2007. Turkiye de viral hepatit epidemiyolojisi yayinlarin irdelenmesi, Yayinların irdelenmesi; p. 10-50.
  • 7. Gurol E, Saban C, Oral O, Cigdem A, Armagan A. Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur J Epidemiol. 2006;21(4):299-305. doi: 10.1007/s10654-006-0001-2. [PubMed: 16685581].
  • 8. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020-6. doi: 10.1016/j.cmi.2015.06.028. [PubMed: 26163105].
  • 9. Toy M, Onder FO, Wormann T, Bozdayi AM, Schalm SW, Borsboom GJ, et al. Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infect Dis. 2011;11:337. doi: 10.1186/1471-2334-11-337. [PubMed: 22151620].
  • 10. European Association For The Study Of The L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167-85. doi: 10.1016/j.jhep.2012.02.010. [PubMed: 22436845].
  • 11. Sayan M, Akhan SC, Meric M. Naturally occurring amino-acid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B. J Viral Hepat. 2010;17(1):23-7. doi: 10.1111/j.1365-2893.2009.01149.x. [PubMed: 19566788].
  • 12. Papatheodoridis GV, Deutsch M. Resistance issues in treating chronic hepatitis B. Future Microbiol. 2008;3(5):525-38. doi: 10.2217/17460913.3.5.525. [PubMed: 18811237].
  • 13. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol. 2006;44(3):593-606. doi: 10.1016/j.jhep.2006.01.001. [PubMed: 16455151].
  • 14. Sheldon J, Rodes B, Zoulim F, Bartholomeusz A, Soriano V. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat. 2006;13(7):427-34. doi: 10.1111/j.1365-2893.2005.00713.x. [PubMed: 16792535].
  • 15. Avellon A, Echevarria JM. Frequency of hepatitis B virus 'a' determinant variants in unselected Spanish chronic carriers. J Med Virol. 2006;78(1):24-36. doi: 10.1002/jmv.20516. [PubMed: 16299725].
  • 16. Locarnini S, Bowden S. Drug resistance in antiviral therapy. Clin Liver Dis. 2010;14(3):439-59. doi: 10.1016/j.cld.2010.05.004. [PubMed: 20638024].
  • 17. Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother. 2008;61(4):766-8. doi: 10.1093/jac/dkn014. [PubMed: 18218641].
  • 18. Teo CG, Locarnini SA. Potential threat of drug-resistant and vaccine-escape HBV mutants to public health. Antivir Ther. 2010;15(3 Pt B):445-9. doi: 10.3851/IMP1556. [PubMed: 20516564].
  • 19. Locarnini SA, Yuen L. Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir Ther. 2010;15(3 Pt B):451-61. doi: 10.3851/IMP1499. [PubMed: 20516565].
  • 20. Sayan M, Cavdar C, Dogan C. Naturally occurring polymerase and surface gene variants of hepatitis B virus in Turkish hemodialysis patients with chronic hepatitis B. Jpn J Infect Dis. 2012;65(6):495-501. [PubMed: 23183201].
  • 21. Vutien P, Trinh HN, Garcia RT, Nguyen HA, Levitt BS, Nguyen K, et al. Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-naive patients. Clin Gastroenterol Hepatol. 2014;12(8):1363-70. doi: 10.1016/j.cgh.2013.11.036. [PubMed: 24342744].
  • 22. Han Y, Huang LH, Liu CM, Yang S, Li J, Lin ZM, et al. Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients. J Gastroenterol Hepatol. 2009;24(8):1417-23. doi: 10.1111/j.1440-1746.2009.05864.x. [PubMed: 19486254].
  • 23. Jardi R, Rodriguez-Frias F, Buti M, Schaper M, Esteban R, Guardia J. Mutations at HBV-polymerase gene associated with entecavir drug resistance in patients not undergoing entecavir therapy. Hepatol. 2006;44:547A.
  • 24. Lampertico P, Viganò M, Facchetti F, Puoti M, Minola E, Suter F, et al. Effectiveness of entecavir for the treatment of NUC-naive chronic hepatitis B patients: a large multicenter cohort study in clinical practice. Hepatol. 2008;48(Suppl 1):707A-8A.
  • 25. Ludwig AD, Goebel T, Adams O, Baumann N, Hauck K, Fey H, et al. Primary resistance mutations against nucleos (t) ide analogues in treatment name patients with hbv-infection. Hepatol. 2008;48(4):701A.
  • 26. Mirandola S, Campagnolo D, Bortoletto G, Franceschini L, Marcolongo M, Alberti A. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. J Viral Hepat. 2011;18(7):212-6. doi: 10.1111/j.1365-2893.2011.01435.x. [PubMed: 21692935].
  • 27. Salpini R, Svicher V, Cento V, Gori C, Bertoli A, Scopelliti F, et al. Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naive to antiviral drugs. Antiviral Res. 2011;92(2):382-5. doi: 10.1016/j.antiviral.2011.08.013. [PubMed: 21920388].
  • 28. Ergunay K, Kahramanoglu Aksoy E, Simsek H, Alp A, Sener B, Tatar G, et al. [Investigation of baseline antiviral resistance in treatment-naive chronic hepatitis B cases]. Mikrobiyol Bul. 2013;47(4):628-35. [PubMed: 24237431].
  • 29. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis. 2006;26(2):162-70. doi: 10.1055/s-2006-939758. [PubMed: 16673294].
  • 30. Sayan M, Akhan SC, Senturk O. Frequency and mutation patterns of resistance in patients with chronic hepatitis B infection treated with nucleos(t)ide analogs in add-on and switch strategies. Hepat Mon. 2011;11(10):835-42. doi: 10.5812/kowsar.1735143X.775. [PubMed: 22224083].
  • 31. Liu Y, Wang CM, Cheng J, Liang ZL, Zhong YW, Ren XQ, et al. Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility. Chin Med J (Engl). 2009;122(13):1585-6. [PubMed: 19719953].
  • 32. Xu Y, Zhang YG, Wang X, Qi WQ, Qin SY, Liu ZH, et al. Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis. World J Gastroenterol. 2015;21(25):7869-76. doi: 10.3748/wjg.v21.i25.7869. [PubMed: 26167087].
  • 33. Osiowy C, Villeneuve JP, Heathcote EJ, Giles E, Borlang J. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol. 2006;44(6):1994-7. doi: 10.1128/JCM.02477-05. [PubMed: 16757589].
  • 34. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatol. 2007;46(1):254-65. doi: 10.1002/hep.21698. [PubMed: 17596850].
  • 35. Amini-Bavil-Olyaee S, Herbers U, Mohebbi SR, Sabahi F, Zali MR, Luedde T, et al. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome. J Hepatol. 2009;51(4):647-54. doi: 10.1016/j.jhep.2009.04.022. [PubMed: 19586679].
  • 36. Sayan M, Akhan SC. Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B. Int J Infect Dis. 2011;15(10):722-6. doi: 10.1016/j.ijid.2011.05.019. [PubMed: 21784687].
  • 37. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatol. 2008;48(1):88-98. doi: 10.1002/hep.22295. [PubMed: 18537180].
  • 38. Clements CJ, Coghlan B, Creati M, Locarnini S, Tedder RS, Torresi J. Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization?. Bull World Health Organ. 2010;88(1):66-73. doi: 10.2471/BLT.08.065722. [PubMed: 20428355].
  • 39. Locarnini S. Transmission of antiviral drug resistant hepatitis B virus: implications for public health and patient management. J Gastroenterol Hepatol. 2010;25(4):649-51. doi: 10.1111/j.1440-1746.2010.06255.x. [PubMed: 20492319].
  • 40. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol. 2002;25(2):97-106. [PubMed: 12367644].
  • 41. Sayan M, Senturk O, Akhan SC, Hulagu S, Cekmen MB. Monitoring of hepatitis B virus surface antigen escape mutations and concomitantly nucleos(t)ide analog resistance mutations in Turkish patients with chronic hepatitis B. Int J Infect Dis. 2010;14 Suppl 3:136-41. doi: 10.1016/j.ijid.2009.11.039. [PubMed: 20382061].
  • 42. Hadziyannis SJ. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol. 2011;55(1):183-91. doi: 10.1016/j.jhep.2010.12.030. [PubMed: 21238520].
  • 43. Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014;20(18):5427-34. doi: 10.3748/wjg.v20.i18.5427. [PubMed: 24833873].
  • 44. Sayan M, Sargin F, Inan D, Sevgi DY, Celikbas AK, Yasar K, et al. HIV-1 Transmitted Drug Resistance Mutations in Newly Diagnosed Antiretroviral-Naive Patients in Turkey. AIDS Res Hum Retroviruses. 2016;32(1):26-31. doi: 10.1089/AID.2015.0110. [PubMed: 26414663].
  • 45. Bagheri Amiri F, Mostafavi E, Mirzazadeh A. HIV, HBV and HCV Coinfection Prevalence in Iran--A Systematic Review and Meta-Analysis. PLoS One. 2016;11(3):151946. doi: 10.1371/journal.pone.0151946. [PubMed: 27031352].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiaion Alert via Google Reader

Cited By: